Symphony Clinical Research Acquired by ICON

October 24, 2019

Acquisition expands Symphony’s ability to offer customers decentralized and hybrid trial solutions globally 

 

Vernon Hills, Illinois, USA, 24 October, 2019 – Symphony Clinical Research, a leading provider of at-home patient and site support services announced today that it has been acquired by ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialization services to pharmaceutical, biotechnology, medical device industries.

The acquisition, concluded in late September, further enhances ICON’s patient, site and data strategy and complements ICON’s existing PMG Research and MeDiNova Research site networks in the US and EMEA. Symphony’s services reduce the travel burden for patients which broadens ICON’s recruitable population, providing patients access to clinical research studies that they may not have otherwise been able to participate in.

Nicki Norris, Chief Executive Officer, Symphony Clinical Research, said: “As the pioneer in alternate-site services, Symphony integrates clinical trial expertise with project management; in-home care and nursing to bring the site visit to the patient wherever they live.  ICON provides Symphony with a great opportunity to extend our services globally and to use our knowledge, infrastructures and network to support ICON to enhance patient recruitment, engagement and retention.” 

Laurie Streling, Chief Operating Officer and Chief Financial Officer, Symphony Clinical Research added: “I couldn’t imagine a better partner for the Symphony team or a better way to advance our mission to improve patients’ lives by accelerating R&D decisions. ICON’s philosophy of focusing innovation on reducing time and cost, together with increasing the quality of clinical trials, is an excellent fit for the culture we have developed at Symphony.”

Symphony Clinical Research would also like to extend their gratitude to their Advisory Committee, who were instrumental in this process—Miller, Cooper & Ltd.; Levenfeld Pearlstein, LLC; and Ziegler.

About Symphony Clinical Research
Symphony Clinical Research is the leading global provider of specialized in-home and alternate-site clinical services. Since 2003, Symphony has been making it convenient to participate in clinical research by bringing study visits to patients, from neonates to geriatrics, in all phases and therapeutic areas of clinical trials.

Symphony has spearheaded the patient-centric in-home study services movement and has continually been at the forefront of innovation in clinical research including decentralized, hybrid, direct-to-patient and virtual trials. We continually strive to perfect the service model through developing more efficient and reliable ways to deliver high-quality results.

Symphony’s services have significantly accelerated the pace of clinical trials by dramatically improving patient recruitment, retention, compliance and site productivity as well as increasing patient and investigator satisfaction.

Further information is available at www.symphonyclinicalresearch.com

About ICON plc
ICON plc is a global provider of outsourced drug development and commercialization solutions and services to the pharmaceutical, biotechnology, medical device and government and public health organizations. The company specializes in the strategic development, management and analysis of programs that support clinical development – from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 99 locations in 40 countries and has approximately 14,600 employees.

Further information is available at www.iconplc.com/patients

Symphony Media Contact

Melissa Hawking | +1.224.424.5843 | mhawking@symphonyclinicalresearch.com

Share